Mersana Therapeutics, Inc. Operating Lease Cost
Mersana Therapeutics, Inc. reported Operating Lease Cost of $3.84 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2025-03-03
- Mersana Therapeutics, Inc. operating lease, cost for the quarter ending 2019-12-31 was $540.00K.
- Mersana Therapeutics, Inc. operating lease, cost for the quarter ending 2019-09-30 was $540.00K.
- Mersana Therapeutics, Inc. operating lease, cost for the quarter ending 2019-06-30 was $540.00K.
- Mersana Therapeutics, Inc. operating lease, cost for the quarter ending 2019-03-31 was $540.00K.
- Mersana Therapeutics, Inc. operating lease, cost for fiscal 2024 was $3.84M, a 0.00% change from fiscal 2023.
- Mersana Therapeutics, Inc. operating lease, cost for fiscal 2023 was $3.84M, a 1.19% increase from fiscal 2022.
- Mersana Therapeutics, Inc. operating lease, cost for fiscal 2022 was $3.79M, a 8.31% increase from fiscal 2021.
- Mersana Therapeutics, Inc. operating lease, cost for fiscal 2021 was $3.50M, a 27.11% increase from fiscal 2020.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2024-12-31 | $3.84M 10-K · filed 2025-03-03 | |||
| 2023-12-31 | $3.84M 10-K · filed 2025-03-03 | |||
| 2022-12-31 | $3.79M 10-K · filed 2025-03-03 | |||
| 2021-12-31 | $3.50M 10-K · filed 2024-02-28 | |||
| 2020-12-31 | $2.75M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $540.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.08M derived: sum of 2 quarters · filed 2022-02-28 | $1.62M derived: sum of 3 quarters · filed 2022-02-28 | $2.16M 10-K · filed 2022-02-28 |
| 2019-09-30 | $540.00K 10-Q · filed 2019-11-06 | $1.08M derived: sum of 2 quarters · filed 2019-11-06 | $1.62M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $540.00K 10-Q · filed 2019-08-08 | $1.08M 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $540.00K 10-Q · filed 2019-05-09 |